Cell line · CVCL_2478
Papers43
1 to 20 of 43
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| MZF1 Inhibits TGFβ-1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Novel tRNA Half mt-5'-tiRNA-Tyr Promotes Colorectal Cancer Proliferation via Inducing HARS2 Succinylation. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cholesterol Reprograms Oxysterol Metabolism via the LOX1/CH25H/CYP7B1 Signaling Axis to Drive Multidrug Resistance in Colorectal Cancer. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Efficacy of an XPO1 inhibitor in combination with irinotecan in a preclinical colorectal cancer model. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DDR1 Promotes Immune Evasion in Colorectal Cancer by Orchestrating IL33-Mediated M2-like Polarization of Tumor-Associated Macrophages. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Colorectal cancer-derived osteopontin rewires macrophages into a pro-metastatic M2 state via the PI3K/AKT/CSF1-CSF1R axis. | Cell Death Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Thimerosal Inhibits Tumor Malignant Progression through Direct Action and Enhancing the Efficacy of PD-1-Based Immunotherapy. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cathepsin-D-mediated MHC class I degradation contributes to immune evasion in colorectal cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Colorectal cancer cell-derived exosomes induce metabolic reprogramming of cancer-associated fibroblasts to promote colorectal cancer growth. | Discov Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal cancer progression. | J Nanobiotechnology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cryptosporidium oocyst wall proteins are true components of the oocyst wall and COWP8 is not required for parasite transmission. | PLoS Pathog | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Ribosomal RNA transcription regulates splicing through ribosomal protein RPL22. | Cell Chem Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Synthesis, Characterization, and Biological Evaluation of N-Methyl Derivatives of Norbelladine. | Molecules | 2024 | Its Methods give the RRID and name the line | PubMed | |
| IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer. | Oncol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum. | Antimicrob Agents Chemother | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mode of action studies confirm on-target engagement of lysyl-tRNA synthetase inhibitor and lead to new selection marker for Cryptosporidium. | Front Cell Infect Microbiol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. | Adv Sci (Weinh) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Broad-Spectrum Inhibitors for Conserved Unique Phosphoethanolamine Methyltransferases in Parasitic Nematodes Possess Anthelmintic Efficacy. | Antimicrob Agents Chemother | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_2478/papers